No profile data available.
TG Therapeutics, Inc. (TGTX) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Morrisville, United States, with about 399 full-time employees.
It reported revenue of $616.29 million for fiscal year 2025, up 87.3% from fiscal year 2024, and net income of $447.18 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $240.34 million, up 70.3% from a year before. United States was its largest region in fiscal year 2025, with 98% of revenue. Its market capitalization was $8.48 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TG Therapeutics reported $616.29 million in revenue for fiscal year 2025, up 87.3% from $329.00 million in fiscal year 2024. In Q2 2026 revenue was $240.34 million.
United States: 98% of revenue by region in fiscal year 2025, followed by International (2%).
$8.48 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Immunovant, Inc. (IMVT), Kiniksa Pharmaceuticals International, plc (KNSA), Aurinia Pharmaceuticals Inc. (AUPH), Viridian Therapeutics, Inc. (VRDN).